Table 1.
Association between CYP4Z1 expression and clinicopathologic features.
| Characteristic | CYP4Z1-positive n = 113 (54.3%) | CYP4Z1-negative n = 95 (45.7%) | P value |
|---|---|---|---|
| Gender | 0.373 | ||
| Male (n = 166, 79.8%) | 94 (56.6%) | 72 (43.4%) | |
| Female (n = 42, 20.2%) | 22 (52.4%) | 20 (47.6%) | |
| Histological type | 0.776 | ||
| Urothelial carcinoma (n = 160, 76.9%) | 91 (56.9%) | 69 (43.1%) | |
| Squamous cell carcinoma (n = 16, 7.7%) | 10 (62.5%) | 6 (37.5%) | |
| Mucinous adenocarcinoma (n = 9, 4.3%) | 5 (55.6%) | 4 (44.4%) | |
| Papillary adenocarcinoma (n = 7, 3.4%) | 3 (42.9%) | 4 (57.1%) | |
| Normal (n = 16, 7.7%) | 4 (25%) | 12 (75%) | |
| Histological grade | |||
| I (n = 67, 34.4%) | 25 (37.9%) | 5 (62.1%) | 0.001 |
| II (n = 81, 42.7%) | 56 (68.3%) | 26 (31.7%) | |
| III (n = 44, 22.9%) | 28 (63.6%) | 16 (36.4%) | |
| Normal (n = 16, 7.7%) | 4 (25%) | 12 (75%) | |
| Histological stage | |||
| 1 (n = 53, 27.6%) | 37 (69.8%) | 16 (30.2%) | 0.035 |
| 2 (n = 101, 52.6%) | 47 (46.5%) | 54 (53.5%) | |
| 3 (n = 34, 17.7%) | 22 (64.7%) | 12 (35.3%) | |
| 4 (n = 4, 2.1%) | 3 (75.0%) | 1 (25%) | |
| Normal (n = 16, 7.7%) | 4 (25%) | 12 (75%) | |
| TNM staging | 0.043 | ||
| T1N0M0 (n = 54, 28.1%) | 37 (68.5%) | 17 (31.5%) | |
| T2N0M0 (n = 101, 52.6%) | 47 (46.5%) | 54 (53.5%) | |
| T3N0M0 (n = 34, 17.7%) | 22 (64.7%) | 12 (35.3%) | |
| T3N1M0 (n = 2, 1.0%) | 2 (100%) | 0 (0%) | |
| T3N2M0 (n = 1, 0.5%) | 1 (100%) | 0 (0%) | |
| Normal (n = 16, 7.7%) | 4 (25%) | 12 (75%) | |